iLite® ADCC Bioassays by Svar Life Science AB

Manufacturer Svar Life Science AB  |  Available Worldwide
The iLite ADCC product portfolio is based on a reporter gene system and offers a convenient and powerful way of measuring the efficacy of antibodies to elicit ADCC in vitro. The portfolio consist of cell lines provided in an “assay-ready” format for a rapid and convenient workflow and further reduction in assay variability, enabling their use in antibody screening, characterization, stability and potency studies. 


iLite® ADCC Bioassays by Svar Life Science AB product image
iLite® ADCC Bioassays
Request Pricing

Receive your quote directly from the manufacturer.



0 Scientists have reviewed this product


Write the First Review

No Reviews

The iLite ADCC product portfolio is based on a reporter gene system and offers a convenient and powerful way of measuring the efficacy of antibodies to elicit ADCC in vitro. The iLite ADCC technology combine a cleverly engineered effector cell, that closely resembles the natural FcγRIIIA signal transduction pathway, with homologous target cells with controlled antigen expression (+) or depletion (-). The portfolio includes: 

Effector Cells

  • iLite® ADCC Effector FcγRIIIa (V) [BM5001]

Target Cells

  • iLite® CD20 (+) Target [BM5010]
  • iLite® CD20 (-) Target [BM5015]
  • iLite® EGFR (+) Target [BM5035]
  • iLite® EGFR (-) Target [BM5036]
  • iLite® HER2 (+) Target [BM5011]
  • iLite® HER2 (-) Target [BM5016]
  • iLite® mTNF-alpha (+) Target [BM5013]
  • iLite® mTNF-alpha (-) Target [BM5014]
  • iLite mVEGF (+) Target [BM5017]
  • iLite® mVEGF (-) Target [BM5018]